Drug Delivery: Inhalation Devices
Drug Delivery: Inhalation Devices
$4,750.00
This Meddevicetracker report includes a discussion of inhalation devices, products, current/forecast markets, competitors, and opportunities in the global markets for inhalation-based drug delivery devices for the treatment of asthma and COPD and much more.
Author: Pharma Intelligence
Publisher: Meddevicetracker
- Description
- Contents
The 2018 combined global prevalence of asthma and COPD was approximately 650.6 million, with asthma accounting for 53% and COPD accounting for the remaining 47%. In 2020, combined sales of asthma and COPD inhalers in the countries covered by this analysis totaled approximately $15.4bn. Of this, asthma devices accounted for 57% and COPD devices accounted for 43%. Market drivers include the growing prevalence of asthma and COPD in certain regions due to the growing and aging population, and the introduction of lucrative triple-combination therapies. Market limiters include generic competition for certain blockbuster drug/device combos, competition for more traditional inhaled corticosteroids from triple-combination therapies, and a decline in cigarette smoking, leading to slowed growth in the prevalence of COPD in some regions. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for inhalation-based drug delivery devices for the treatment of asthma and COPD; these include metered dose inhalers (MDIs) and dry powder inhalers (DPIs). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), and Japan. The forecast range for this report is 2020–25.
Executive Summary …………………………………………………………………….. ES-1
i. Respiratory disease prevalence ………………………………………………………………………… ES-1
ii. Inhalation drug delivery devices market ……………………………………………………………. ES-1
a. Geographic market analysis …………………………………………………………………. ES-2
iii. Market drivers and limiters …………………………………………………………………………….. ES-3
iv. Market leaders …………………………………………………………………………………………….. ES-4
v. Methodology ………………………………………………………………………………………………… ES-4
Exhibit ES-1: Inhalation drug delivery devices, market forecast, by product segment ($m), 2020–25 …………………………………………………………… ES-2
Exhibit ES-2: Inhalation drug delivery devices, market forecast, by region ($m), 2020–25………………………………………………………………………….. ES-3
1. Inhalation Drug Delivery Technology ……………………………………………. 1-1
1.1 Technology …………………………………………………………………………………………………… 1-1
1.1.1 Metered dose inhalers ……………………………………………………………………… 1-1
1.1.2 Dry powder inhalers …………………………………………………………………………. 1-2
1.1.3 Nebulizers ………………………………………………………………………………………. 1-2
1.2 Impact of COVID-19 ……………………………………………………………………………………….. 1-3
1.3 Bibliography …………………………………………………………………………………………………. 1-5
2. Inhalation Devices for Asthma …………………………………………………….. 2-1
2.1 Epidemiology ……………………………………………………………………………………………….. 2-2
2.2 Products ………………………………………………………………………………………………………. 2-3
2.2.1 Regulatory guidelines ……………………………………………………………………….. 2-3
2.2.2 AstraZeneca ……………………………………………………………………………………. 2-3
2.2.3 Boehringer Ingelheim ……………………………………………………………………….. 2-3
2.2.4 GlaxoSmithKline ………………………………………………………………………………. 2-4
2.2.5 Organon…………………………………………………………………………………………. 2-4
2.2.6 Teva …………………………………………………………………………………………….. 2-4
2.2.7 Vectura ………………………………………………………………………………………….. 2-5
2.2.8 Emerging products …………………………………………………………………………… 2-6
©2021 Meddevicetracker ii #MDT21015
Drug Delivery: Inhalation Devices Table of Contents
2.3 Market analysis …………………………………………………………………………………………….. 2-7
2.3.1 US market forecast ………………………………………………………………………….. 2-8
2.3.2 5 Euro market forecast ……………………………………………………………………. 2-12
2.3.3 Japan market forecast …………………………………………………………………….. 2-15
2.4 Bibliography ……………………………………………………………………………………………….. 2-19
Exhibit 2-1: Asthma, prevalence by region (000s), 2018–27 ……………………………………….. 2-2
Exhibit 2-2: Selected inhaled asthma treatment products, 2021 …………………………………. 2-6
Exhibit 2-3: Inhaled asthma treatment products, combined market forecast ($m), 2020–25 …………………………………………………………………………………………………. 2-8
Exhibit 2-4: Inhaled asthma treatment products, US market forecast ($m), 2020–25……. 2-11
Exhibit 2-5: Inhaled asthma treatment products market, US share by supplier, 2020 ……. 2-12
Exhibit 2-6: Inhaled asthma treatment products, 5 Euro market forecast ($m), 2020–25 . 2-14
Exhibit 2-7: Inhaled asthma treatment products market, 5 Euro share by supplier, 2020 . 2-15
Exhibit 2-8: Inhaled asthma treatment products, Japan market forecast ($m), 2020–25 .. 2-17
Exhibit 2-9: Inhaled asthma treatment products market, Japan share by supplier, 2020 .. 2-18
3. Inhalation Devices for Chronic Obstructive Pulmonary Disease ………….. 3-1
3.1 Epidemiology ……………………………………………………………………………………………….. 3-1
3.2 Products ………………………………………………………………………………………………………. 3-2
3.2.1 AstraZeneca ……………………………………………………………………………………. 3-2
3.2.2 Boehringer Ingelheim ……………………………………………………………………….. 3-3
3.2.3 GlaxoSmithKline ………………………………………………………………………………. 3-3
3.2.4 Sumitomo Dainippon ……………………………………………………………………….. 3-4
3.2.5 Emerging products …………………………………………………………………………… 3-4
3.3 Market analysis …………………………………………………………………………………………….. 3-6
3.3.1 US market forecast ………………………………………………………………………….. 3-7
3.3.2 5 Euro market forecast ……………………………………………………………………. 3-11
3.3.3 Japan market forecast …………………………………………………………………….. 3-14
3.4 Bibliography ……………………………………………………………………………………………….. 3-17
Exhibit 3-1: COPD, epidemiology by region (000s), 2018–27 ………………………………………. 3-2
Exhibit 3-2: Selected inhaled COPD treatment products, 2021……………………………………. 3-5
Exhibit 3-3: Inhaled COPD treatment products, combined market forecast ($m), 2020–25 …………………………………………………………………………………………………. 3-7
Exhibit 3-4: Inhaled COPD treatment products, US market forecast ($m), 2020–25 ……… 3-10
Exhibit 3-5: Inhaled COPD treatment products market, US share by supplier, 2020 ……… 3-11
Exhibit 3-6: Inhaled COPD treatment products, 5 Euro market forecast ($m), 2020–25 … 3-13
Exhibit 3-7: Inhaled COPD treatment products market, 5 Euro share by supplier, 2020 … 3-14
Exhibit 3-8: Inhaled COPD treatment products, Japan market forecast ($m), 2020–25….. 3-15
Exhibit 3-9: Inhaled COPD treatment products market, Japan share by supplier, 2020….. 3-16
Appendix: Company Listing ……………………………………………………………. A-1
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation ... 
Sign up to the